Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients
January 09, 2025 08:30 ET
|
Alkeus Pharmaceuticals
Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month...
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025 10:52 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14.
Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
December 05, 2024 08:30 ET
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of...
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
November 18, 2024 09:16 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as a treatment for Stargardt Disease
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
October 23, 2024 09:00 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
July 18, 2024 10:20 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer
July 16, 2024 09:00 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals appoints Tamara Dillon as Chief Human Resources Officer
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
July 02, 2024 08:30 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer.